According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, SVB Leerink set a $8.24 target price on shares of Sientra and gave the company a buy rating in a research note on Wednesday, July 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $9.19.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Tuesday, August 10th. The medical instruments supplier reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.13). Sientra had a negative net margin of 119.58% and a negative return on equity of 901.29%. The business had revenue of $20.10 million during the quarter, compared to analyst estimates of $20.27 million. Equities research analysts predict that Sientra will post -0.78 EPS for the current fiscal year.
In other news, CEO Ronald Menezes acquired 5,800 shares of the stock in a transaction dated Thursday, August 12th. The stock was bought at an average price of $6.98 per share, with a total value of $40,484.00. Following the completion of the purchase, the chief executive officer now directly owns 505,800 shares of the company’s stock, valued at approximately $3,530,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Oliver Christian Bennett sold 3,615 shares of the company’s stock in a transaction that occurred on Friday, August 20th. The shares were sold at an average price of $6.93, for a total value of $25,051.95. Following the completion of the sale, the insider now owns 80,483 shares in the company, valued at $557,747.19. The disclosure for this sale can be found here. In the last three months, insiders bought 8,698 shares of company stock valued at $59,002. 1.10% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in SIEN. X Square Capital LLC grew its stake in shares of Sientra by 0.7% during the 2nd quarter. X Square Capital LLC now owns 291,001 shares of the medical instruments supplier’s stock worth $2,316,000 after acquiring an additional 1,941 shares during the period. Parametric Portfolio Associates LLC boosted its position in shares of Sientra by 8.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 28,344 shares of the medical instruments supplier’s stock valued at $226,000 after acquiring an additional 2,261 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Sientra by 10.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,572 shares of the medical instruments supplier’s stock valued at $267,000 after buying an additional 3,093 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Sientra during the 1st quarter valued at about $33,000. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Sientra by 41.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 17,170 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 5,000 shares in the last quarter. 88.81% of the stock is owned by hedge funds and other institutional investors.
Sientra Company Profile
Sientra, Inc operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM.
See Also: Options Trading – What is a Straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.